Chicago
Polo G’s The Goat Laments Chicago’s Violence with Poetic Precision: Review
The Lowdown: In this winner-take-all economy, the owner class is shrinking faster than you can read a foreclosure notice. Yet, Polo G’s talent for quivery, upwardly inflected sing-rapping made him a homeowner. He has a backyard. He can come and go as he pleases. No more agonizing wait times at apartment security checkpoints; no more having to dodge the prying eyes of too-inquisitive neighbors. On his sophomore album, The Goat, Polo G — who was raised in a squat brick mid-rise on Chicago’s Near North Side or, as he calls it, “the zoo” — marvels at his sudden freedom of movement. But he’s restless and slightly remorseful in his new life. Privacy is one of those benefits that redounds down to the upper, petty bourgeois. As long as his friends on Sedgwick Street are still living under state su...
‘Empire’ Star Bryshere Gray’s Dog Accused of Causing $26K In Home Damage
Source: FOX / Getty Bryshere Gray may have been the “top dog” on the hit show, Empire, but it seems his dog in real life is being accused of causing some pretty extensive damages at his rental home and the landlord wants the money back. According to TMZ, Chicago landlords Vinod Venugopal and Payal Shah sued the Empire star after claiming that Gray and his dog “terrorized” the building he rented while filming the hit show’s final season. In court documents obtained by the site, the landlords say they rented Gray a condo inside their four-unit Chicago complex in August 2019, it was there that they claim Gray, among other things, left his dog inside the condo for extended periods of time. They also claim the dog was left unattended in common areas in the complex and urinated an...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
